High Throughput Screening Equipment Company Profile
Aurora Biomed provides enabling technologies, assay services, and reagents for drug discovery research, drug safety screening, liquid-handling, and laboratory automation. We are headquartered in Vancouver, BC, Canada, but have global sales, support, and service.
Ion Channel Research
The initial focus of Aurora Biomed was on high-throughput ion channel drug discovery so as to address the recent shift of resources in the pharmaceutical industry towards addressing drug safety issues earlier in the discovery process. The shift was compelled by the issue of drug-induced QT-prolongation and cardiac arrhythmias and the emergence of the S7B, E14 guidance documents for drug safety assessment. High-throughput screening (HTS) of test compounds early in the discovery process decreases the cost of drug discovery as compounds with potential to cause QT-prolongation are removed before substantial development has taken place.
Aurora Biomed has recently expanded its focus to include liquid-handling and laboratory automation. Automation of liquid-handling applications removes variability from repetitive liquid-related benchwork, thereby increasing reliability. With these new product families, we will increase efficiency of ion channel drug discovery. Moreover, we are endeavouring to go beyond ion channel drug discovery and enable research efforts surrounding other molecular targets.
In order to provide HTS solutions for all ion channel researchers, Aurora Biomed offers assay services whereby compounds will be tested on ion channels of interest for functional interaction. Typically, we will provide an 8-point IC50 curve. The compounds will be tested in quadruplicate with a concentration range of 0.001 to 10ÁM, unless otherwise specified.
Address: 1001 East Pender Street, Vancouver,